Identification of GDF-6 blocking antibodies as anti-melanoma therapeutics by Monir, Ejemel et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Research Retreat 
2016 UMass Center for Clinical and 
Translational Science Research Retreat 
May 20th, 12:30 PM 
Identification of GDF-6 blocking antibodies as anti-melanoma 
therapeutics 
Ejemel Monir 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat 
 Part of the Cancer Biology Commons, Immunoprophylaxis and Therapy Commons, Medical 
Immunology Commons, and the Neoplasms Commons 
Monir E, Wisheart D, Gramann A, Venkatesan A, Klempner MS, Ceol CJ, Wang Y. (2016). Identification of 
GDF-6 blocking antibodies as anti-melanoma therapeutics. UMass Center for Clinical and Translational 
Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2016/posters/
15 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
UMass CCTS Research Retreat 
Poster Abstract Submission 
 
Identification of GDF-6 blocking antibodies as anti-melanoma therapeutics 
 
Monir Ejemel1, Danielle Wisheart1, Alec Gramann2, Arvind Venkatesan2, Mark S. Klempner1, Craig J. Ceol2#, Yang 
Wang1# 
 
1MassBiologics, University of Massachusetts Medical School, Boston, Massachusetts, USA 
2Program of Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA 
 
#Co-corresponding authors and Co-PIs for NHMPP award 
 
Through comparative oncogenomic studies and functional analyses, we have identified the bone 
morphogenetic protein (BMP) factor GDF6 as a new melanoma oncogene. The secreted, carboxy-
terminal portion of GDF6 is the active form that binds to cell-surface receptors to initiate BMP signaling. 
Targeted antibodies directed against secreted proteins are a proven therapeutic modality in several 
diseases. 
 
To develop therapeutic antibodies against the active form of GDF6, we generated a panel of monoclonal 
antibodies. Due to the high similarity of human and mouse GDF6 proteins, the C-terminal GDF6 protein 
was expressed as bacterial recombinant protein with fusion tags to enhance immunogenicity.  The 
Expresso Screening System (Lucigen) was used to select fusion tags, and MBP and SlyD were chosen for 
optimal protein solubility and purification recovery.  Ten CD1 mice were immunized with GDF6-MBP 
fusion protein and robust immune responses were observed in all animals after 5 immunizations. Animals 
were sacrificed for hybridoma fusion, and hybridoma clones were screened by ELISA using GDF6-SlyD 
fusion protein to select clones with specific binding activity to GDF6. Over 70 monoclonal antibodies 
were identified with strong reactivity to GDF6, and a subset has been shown to recognize the endogenous, 
secreted form of GDF6 via western blot. These antibodies will be screened for their activity to block 
GDF6 binding to melanoma cells and ability to inhibit downstream signaling using both in vitro assays 
and in vivo xenograft models.  
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